Identification of VVD-214/RO7589831, a Clinical-Stage, Covalent Allosteric Inhibitor of WRN Helicase for the Treatment of MSI-High Cancers

Werner syndrome helicase (WRN) has emerged as a compelling therapeutic target for microsatellite instability-high (MSI-H) cancers, owing to its selective dependency on the helicase activity of WRN. Despite the inherent challenges in targeting helicases, our chemoproteomics approach enabled the identification of compounds that covalently engage C727 within an allosteric pocket of WRN, thereby inhibiting its ability to unwind DNA. Through optimization of each molecular component, particularly focusing on the vinyl sulfone warhead and C2 substitution at the pyrimidine core, an optimal balance of intrinsic reactivity, inhibitory potency, and metabolic stability was achieved, culminating in the identification of VVD-214/RO7589831. This process underscored the tunability of the vinyl sulfone warhead and its effectiveness in covalent drug discovery. VVD-214 induced tumor regression in MSI-H colorectal cancer models and is being evaluated as a promising therapeutic candidate for MSI-H cancers.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2025-09-18
DOI
https://doi.org/10.1021/acs.jmedchem.5c01805
Citations
2
Primary Topic
Cancer-related gene regulation
Type
article
Field-Weighted Citation Impact
1.61
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Identification of VVD-214/RO7589831, a Clinical-Stage, Covalent Allosteric Inhibitor of WRN Helicase for the Treatment of MSI-High Cancers

Jason C. Green, Matthew P. Patricelli, Kelsey N. Lamb, Zachary A. Owyang et al.
2 citations
Journal of Medicinal Chemistry
Cancer-related gene regulation
1.61
article

Identification of VVD-214/RO7589831, a Clinical-Stage, Covalent Allosteric Inhibitor of WRN Helicase for the Treatment of MSI-High Cancers

Jason C. Green, Matthew P. Patricelli, Kelsey N. Lamb, Zachary A. Owyang, Melissa Hoffman, Shota Kikuchi, Aaron N. Snead, Benjamin D. Horning, Thomas Glaza, Steffen M. Bernard, David S. Weinstein, Robert D. Malmstrom, Chu-Chiao Wu, Xiaodan Song, Gabriel M. Simon, Kent T. Symons, Laurence E. Burgess, Jonathan Pollock, Ali Tabatabaei, Paige Ashby, Betty Lam, Martha K. Pastuszka, John J. Sigler, Kristen A. Baltgalvis, Don C. Rogness
article en
2 citations

Abstract

Werner syndrome helicase (WRN) has emerged as a compelling therapeutic target for microsatellite instability-high (MSI-H) cancers, owing to its selective dependency on the helicase activity of WRN. Despite the inherent challenges in targeting helicases, our chemoproteomics approach enabled the identification of compounds that covalently engage C727 within an allosteric pocket of WRN, thereby inhibiting its ability to unwind DNA. Through optimization of each molecular component, particularly focusing on the vinyl sulfone warhead and C2 substitution at the pyrimidine core, an optimal balance of intrinsic reactivity, inhibitory potency, and metabolic stability was achieved, culminating in the identification of VVD-214/RO7589831. This process underscored the tunability of the vinyl sulfone warhead and its effectiveness in covalent drug discovery. VVD-214 induced tumor regression in MSI-H colorectal cancer models and is being evaluated as a promising therapeutic candidate for MSI-H cancers.

Journal of Medicinal ChemistryVol. 68(24)
Vividion Therapeutics (United States) (US)
Openalex Percentile: Top 15%
Cancer-related gene regulation
1.61
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.